HSG Blog

Game-changing gene-silencing therapies for HD

VITAL SIGNS NAME: Amber Southwell, PhD TITLE: Assistant Professor of Neuroscience, Burnett School of Biomedical Sciences, University of Central Florida...

Research Round-Up

By: Lise Munsie, PhD In neurons… The HD Induced Pluripotent Stem Cell (iPSC) consortium differentiated HD patient iPSCs into neuronal...

Highlights of CHDI

The 12th Annual CHDI HD Therapeutics Conference was held in St. Julian’s, Malta, April 24–27, 2017. By: Nicholas Caron, PhD...

HD Research Around the World: Brazil

By: Irina Kerkis, PhD Little is known formally about the exact number of HD patients and individuals at risk in...

Highlights from the Journal of HD

By: Jennifer A. Simpson, LMSW and George J. Yohrling, PhD Original Article: Simpson JA, Lovecky D, Kogan J, et al....

Editor’s Letter

Welcome to the 17th edition of HD Insights, timed for release at the 21st International Congress of Parkinson Disease and...

We need you!

HSG currently has two surveys in which your input is invaluable. We know there are a lot of surveys going...

FDA Approves Second Drug for Huntington Disease Symptom

The U.S. Food and Drug Administration (FDA) today approved SD-809 (deutetrabenazine), the second drug approved for use in the United...

Seeking Survey Participants

If you are someone with HD, or a family member, friend or caregiver of a person living with HD, please...

Click to sign up for updates on HSG trials

Help4HD Blog Radio features I am the DIFFERENCE campaign

Help4HD gave the Huntington Study Group the opportunity on its radio show to update the community on our many current...

1 2 3 4 5 22